ACTU · Actuate Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| R&D | $2.57M | - | $2.18M | $2.76M | $6.86M | - | $5.76M | $4.37M |
| SG&A | $3.14M | - | $3.29M | $3.20M | $912.8K | - | $714.2K | $807.2K |
| Total Operating Expenses | $5.71M | - | $5.47M | $5.97M | $7.77M | - | $6.48M | $5.44M |
| D&A | - | - | - | - | - | - | - | - |
| Operating Income | ($5.71M) | - | ($5.47M) | ($5.97M) | ($7.77M) | - | ($5.39M) | ($5.58M) |
| Interest Expense | $5.1K | - | $5.1K | $5.1K | $5.1K | - | $3.5K | $5.1K |
| Income Tax | - | - | - | - | - | - | - | - |
| Net Income | ($5.63M) | - | ($5.41M) | ($5.95M) | ($6.32M) | - | ($6.34M) | ($5.52M) |
| EPS - Basic | ($0.24) | - | ($0.25) | ($0.30) | ($5.40) | - | ($0.55) | ($4.20) |
| EPS - Diluted | ($0.24) | - | ($0.25) | ($0.30) | ($5.40) | - | ($4.31) | ($4.20) |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.13M | $13.16M | $16.92M | $6.49M | $3.89M | $8.64M | $13.52M | $351.7K |
| Accounts Receivable | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.20M | $1.52M | $1.25M | $3.17M | $2.64M | $1.92M | $2.33M | $5.89M |
| Current Assets | $8.52M | $13.64M | $17.44M | $6.69M | $4.25M | $9.21M | $14.26M | $549.7K |
| Total Assets | $8.91M | $14.04M | $17.71M | $6.97M | $4.48M | $9.32M | $14.26M | $1.73M |
| Current Liabilities | $4.72M | $5.71M | $6.37M | $9.20M | $9.15M | $8.80M | $8.50M | $20.07M |
| Long-term Debt | - | - | - | - | - | - | - | - |
| Total Liabilities | $5.13M | $6.11M | $6.78M | $9.62M | $9.57M | $9.21M | $8.90M | $21.81M |
| Stockholders' Equity | $3.78M | $7.92M | $10.94M | ($2.65M) | ($5.09M) | $104.2K | $5.36M | ($80.50M) |
| Retained Earnings | ($160.23M) | ($154.61M) | ($150.05M) | ($144.65M) | ($138.70M) | ($132.38M) | ($125.93M) | ($105.09M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($5.02M) | - | - | - | ($5.25M) | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - |
| Financing Cash Flow | ($8.1K) | - | - | - | $4.36M | - | - | - |
| CapEx | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||
| Gross margin | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - |
| Return on assets | -63.1% | - | -30.5% | -85.4% | -140.9% | - | -44.4% | -319.2% |
| Return on equity | -148.7% | - | -49.4% | 224.2% | 124.2% | - | -118.3% | 6.9% |
| Return on invested capital | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||
| Current ratio | 1.80 | 2.39 | 2.74 | 0.73 | 0.46 | 1.05 | 1.68 | 0.03 |
| Quick ratio | 1.80 | 2.39 | 2.74 | 0.73 | 0.46 | 1.05 | 1.68 | 0.03 |
| Cash ratio | 1.72 | 2.31 | 2.66 | 0.71 | 0.42 | 0.98 | 1.59 | 0.02 |
| Leverage | ||||||||
| Debt / Equity | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest coverage | -1127.2x | - | -1080.9x | -1179.2x | -1531.4x | - | -1545.7x | -1100.2x |
| Equity multiplier | 2.35 | 1.77 | 1.62 | -2.63 | -0.88 | 89.44 | 2.66 | -0.02 |
| Liabilities / Assets | 0.58 | 0.44 | 0.38 | 1.38 | 2.13 | 0.99 | 0.62 | 12.60 |
| Efficiency | ||||||||
| Asset turnover | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - |
| Valuation | ||||||||
| P / E | - | - | - | - | - | - | - | - |
| P / B | 17.0x | - | 13.1x | - | - | - | 15.0x | - |
| P / S | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| Growth | ||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 26.6% | - | -1.5% | -6.9% | - | - | - | - |
| Net income growth (YoY) | 10.9% | - | 14.7% | -7.7% | - | - | - | - |
| EPS growth (YoY) | 95.6% | - | 94.2% | 92.9% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | 7505.6% | 104.1% | 96.7% | - | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ACTUATE THERAPEUTICS against the 5 most active filers in the same SIC group.